Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYeung‐Chul MunSPSungho ParkSLSemin Lee

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals that baseline factors influence molecular response in chronic myeloid leukemia, suggesting approaches to improve treatment-free remission.

Key Points

  • Successful TKI discontinuation in chronic myeloid leukemia requires effective molecular response monitoring.
  • At 48 months, treatment-free remission rates were reported at 70.3%, highlighting retention challenges.
  • Observational analysis of patients revealed significant connections between molecular response and minimal residual disease.
  • Factors affecting TFR emphasize the need for tailored monitoring strategies to mitigate risks of relapse.

Cite This Study

Mun et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e128https://doi.org/10.1182/blood-2025-2002
View Full Paper
Ask AI
Bookmark
Share